SARS-CoV-2

• Specific detection of IgG antibodies against SARS-CoV-2 using the S1 domain of the spike protein including the immunologically relevant receptor binding domain (RBD)
• RBD represents important target antigen for virus neutralising antibodies
• Excellent performance and good correlations with neutralisation tests confirmed in external studies
• Programmes for vaccine development worldwide are based on the spike protein as the antigen
• Fully automated processing and evaluation possible
• Also validated for the use of dried capillary blood (dried blood spots – DBS) as alternative sample material; fully automated DBS processing possible

Customer comments and testimonials about this ELISA

^{*Optimized for processing with the EUROLabWorkstation ELISA}

^{*Borderline results were not included. To determine the diagnostic sensitivity, samples from patients with confirmed SARS-CoV-2 infection were analysed. The sensitivity therefore corresponds to the prevalence of antibodies against SARS-CoV-2 in COVID-19 infected persons.}

^{It is possible that no antibodies have formed yet in the persons who tested negative. In some isolated cases the onset of antibody secretion was detected only after a period of 4 – 6 weeks post onset of symptoms.}

^{*Borderline results were not included}

• Sensitive detection of IgG antibodies against SARS-CoV-2 using the nucleocapsid protein
• Antigen with the strongest immune dominance in the coronavirus family
• Optimised specificity of the ELISA due to the use of a modified nucleocapsid protein (NCP) that only contains diagnostically relevant epitopes
• Fully automated processing and evaluation possible
• Also validated for the use of dried capillary blood (dried blood spots – DBS) as alternative sample material; fully automated DBS processing possible

^{*Optimized for processing with the EUROLabWorkstation ELISA}

^{*Borderline results were not included. To determine the diagnostic sensitivity, samples from patients with confirmed SARS-CoV-2 infection were analysed. The sensitivity therefore corresponds to the prevalence of antibodies against SARS-CoV-2 in COVID-19 infected persons.}

^{*Borderline results were not included.}

• Sensitive detection of IgG antibodies against SARS-CoV-2 using the nucleocapsid protein
• Antigen with the strongest immune dominance in the coronavirus family
• Optimised specificity of the ELISA due to the use of a modified nucleocapsid protein (NCP) that only contains diagnostically relevant epitopes
• Fully automated processing and evaluation possible
• Also validated for the use of dried capillary blood (dried blood spots – DBS) as alternative sample material; fully automated DBS processing possible

^{*Optimized for processing with EUROIMMUN Analyzer I / I-2P and Sprinter XL}

^{*Borderline results were not included. To determine the diagnostic sensitivity, samples from patients with confirmed SARS-CoV-2 infection were analysed. The sensitivity therefore corresponds to the prevalence of antibodies against SARS-CoV-2 in COVID-19 infected persons.}

^{*Borderline results were not included.}

• Sensitive ELISA for the determination of IgA against SARS-CoV-2
• Use of the S1 domain of the spike protein as the antigen
• For monitoring of the immune response after positive direct pathogen detection
• Fully automated processing and evaluation possible

^{*Borderline results were not included. To determine the diagnostic sensitivity, samples from patients with confirmed SARS-CoV-2 infection were analysed. The sensitivity therefore corresponds to the prevalence of antibodies against SARS-CoV-2 in COVID-19 infected persons.}

^{*Borderline results were not included}

1. EUROIMMUN Automation Solutions:

EUROLabWorkstation ELISA, Analyzer I, Analyzer I-2P and Sprinter XL

• Automation of the Anti-SARS-CoV-2 ELISAQuick and reliable ELISA processing
• Automation of the Anti-SARS-CoV-2 NCP ELISAQuick and reliable ELISA processing
• High-throughput COVID-19 diagnosticsOptimised ELISA kit format for EUROLabWorkstation ELISA

For further information on our automation options, please contact our experts of product management for instruments and software.

2. Processing on all common open ELISA platforms

Products may not be licensed in accordance with the laws and regulations in all countries.

Please contact your
local distributor for further information.